APA (7th ed.) Citation

NJ, S., M, M., F, O., L, N., W, M., G, M., . . . H, K. (2023). A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. Journal of hematology & oncology, 16(1), 73. https://doi.org/10.1186/s13045-023-01476-8

Chicago Style (17th ed.) Citation

NJ, Short, et al. "A Phase 1/2 Study of Azacitidine, Venetoclax and Pevonedistat in Newly Diagnosed Secondary AML and in MDS or CMML After Failure of Hypomethylating Agents." Journal of Hematology & Oncology 16, no. 1 (2023): 73. https://doi.org/10.1186/s13045-023-01476-8.

MLA (9th ed.) Citation

NJ, Short, et al. "A Phase 1/2 Study of Azacitidine, Venetoclax and Pevonedistat in Newly Diagnosed Secondary AML and in MDS or CMML After Failure of Hypomethylating Agents." Journal of Hematology & Oncology, vol. 16, no. 1, 2023, p. 73, https://doi.org/10.1186/s13045-023-01476-8.